Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $190.00 at The Goldman Sachs Group

Charles River Laboratories International (NYSE:CRL) had its price objective reduced by research analysts at The Goldman Sachs Group from $220.00 to $190.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 15.24% from the stock’s current price.

A number of other research analysts have also recently weighed in on CRL. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. Finally, Bank of America dropped their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $204.38.

Charles River Laboratories International Trading Down 1.2 %

Shares of Charles River Laboratories International stock opened at $164.88 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a fifty day moving average price of $186.75 and a 200 day moving average price of $197.24. Charles River Laboratories International has a 1 year low of $160.85 and a 1 year high of $275.00. The stock has a market cap of $8.43 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the company posted $2.72 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. Equities research analysts predict that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of CRL. American Century Companies Inc. boosted its holdings in Charles River Laboratories International by 4.6% in the 2nd quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 291 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Charles River Laboratories International by 74.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock valued at $833,000 after acquiring an additional 1,721 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at approximately $124,000. ProShare Advisors LLC raised its stake in shares of Charles River Laboratories International by 6.2% in the 2nd quarter. ProShare Advisors LLC now owns 9,975 shares of the medical research company’s stock valued at $2,061,000 after acquiring an additional 583 shares during the period. Finally, Public Sector Pension Investment Board raised its stake in shares of Charles River Laboratories International by 77.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 1,982 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 867 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).